Media Center

Attorney General J.B. Van Hollen Applauds Recent Action by the U.S. Food and Drug Administration (FDA) to Prevent Prescription Drug Abuse

 

“Prescription drug abuse has reached epidemic levels and needs to be fought on a variety of fronts.  It is gratifying to me that the problem has been recognized, and is being dealt with, by both the pharmaceutical industry and the FDA,” Attorney General Van Hollen said.

 

MADISON — Attorney General J.B. Van Hollen expressed his thanks and appreciation to the U.S. Food and Drug Administration (FDA) for its April 16, 2013, decision to approve abuse-deterrent labeling for a reformulated OxyContin tablet produced by Purdue Pharma L.P.  The new labeling indicates that the time-release pain reliever, which has been the subject of prevalent abuse, has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route (snorting).  

 

The FDA also has determined that the original formulation of OxyContin, without the abuse-deterrent features, will no longer be allowed and that it will not approve generic formulations that rely on the approval of the original OxyContin.  The FDA press release making these announcements can be found at the following link:   FDA News Release

 

In a letter dated March 11, 2013, Attorney General Van Hollen joined a bipartisan group of state Attorneys General in urging this action.  A copy of that letter is available here.

 

Regarding the recent FDA action, Attorney General Van Hollen said:

 

Prescription drug abuse has reached epidemic levels and needs to be fought on a variety of fronts.  It is gratifying to me that the problem has been recognized, and is being dealt with, by both the pharmaceutical industry and the FDA.  Government action and regulation is not the answer to every problem.  However, when it comes to keeping our children safe by preventing the abuse of dangerous substances, government has an important role to play.  My thanks go out to the Food and Drug Administration.